Our Research Program

S&PAA’s research program, launched in 2020, is designed to complement early-stage and clinical research into schizophrenia’s origins, diagnosis and treatment by delivering insights on the personal and societal impact of schizophrenia. We have conducted the following research to date:

We also are involved in national efforts to accelerate treatment development and improve outcomes:

  • We are a member of the Steering Committee of the Schizophrenia Spectrum Biomarkers Consortium. Led by the Stanley Center for Psychiatric Research, the objective is to gain insight into disease mechanisms (molecular and cellular “triggers”), stratify patients within the disease spectrum and validate candidates for drug development by seeking and analyzing biomarkers in cerebrospinal fluid.

Only with more comprehensive, accurate data and analysis can the U.S. develop targeted policies and ultimately a better, more equitable system of care for people living with schizophrenia.

We welcome partnership to solve this societal issue. Contact us if you are interested in a research collaboration.

AdobeStock_58368809_web2
AdobeStock_117959885_web

We believe in recovery and a cure for schizophrenia.
Join us on this journey today.

Thanks to a generous donor, your gift will be matched, up to $25,000, and your impact doubled to help S&PAA’s critical work.

We believe in recovery and a cure for schizophrenia. Donate today.